Skip to Content
  • Arguing About Zafgen’s Chances

    It’s been a wild ride for Zafgen and those following the company, and things are nowhere near over. Back in December, it became clear that two patients ha… Read More
  • Mannkind’s Last Stand

    Back in October, I said that Mannkind (MNKD) “looks doomed”. To be honest, you could have said that about them and their inhaled-insulin drug Afrezz… Read More
  • Big Trouble For Zafgen and Beloranib

    Zafgen went through a very rough patch back in October when it turned out that a patient in their key Phase III trial in Prader-Willi syndrome died. P-W patient… Read More
  • Fewer Die – But Why?

    Well, here’s an interesting situation: a drug that seems to have a definite benefit, but not for the reasons anyone expected, and not for reasons that any… Read More
  • Is Everything Getting Fatter?

    Here’s a weird and interesting paper to think about. There’s an unfortunately clear trend in human populations towards obesity, which seems to have… Read More
  • Unkind to Mannkind

    Last time I mentioned Mannkind and their inhaled-insulin product (Afrezza) around here was when Oliver Brandicourt was announced as taking over at Sanofi. But I… Read More
  • How Not to Handle Your Clinical Data

    We turn now to Orexigen, one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, c… Read More
Page 2 of 1512345...10...Last »